J. David Campbell

Blog Entry Image

Measuring the Value of a Drug

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

J. David Campbell portrait

J. David Campbell

Partner, Health & Life Sciences, Oliver Wyman
Joseph Mocanu portrait

Joseph Mocanu

Principal, Health & Life Sciences, Oliver Wyman
Blog Entry Image

Striking a Balance Between Drug Costs and Best Care

Direct-purchase agreements are being floated as a price-control strategy. But how is value defined? And when might low cost come at the expense of true value?

J. David Campbell portrait

J. David Campbell

Partner, Health & Life Sciences, Oliver Wyman

Aaron Shapiro

Senior Consultant, Oliver Wyman
Blog Entry Image

Entresto: Pharma's Litmus Test for Value-Driven Healthcare?

Last week Reuters reported that Novartis plans to use a novel pricing model when it launches its new heart failure drug Entresto. David Campbell, an Oliver Wyman Partner who specializes in valuing new drugs, breaks down how this new model could impact the traditional pharma-payer-provider dynamic.

J. David Campbell portrait

J. David Campbell

Partner, Health & Life Sciences, Oliver Wyman